Current Report Filing (8-k)
May 17 2019 - 04:15PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of report (date of earliest event reported):
May 16, 2019
_____________________
TONIX PHARMACEUTICALS HOLDING CORP.
(Exact name of registrant as specified in
its charter)
Nevada
|
001-36019
|
26-1434750
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
509 Madison Avenue, Suite 1608, New York, New
York 10022
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including
area code:
(212) 980-9155
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered
pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock
|
TNXP
|
The NASDAQ Global Market
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
(b) On May 16, 2019, Dr. Donald W. Landry
notified the Board of Directors (the “Board”) of Tonix Pharmaceuticals Holding Corp. (the “Company”) that
he was resigning from the Board effective immediately. Dr. Landry did not resign from the Board due to any disagreement with the
Company on any matter relating to the Company’s operations, policies or practices.
Item 7.01
|
Regulation FD Disclosure.
|
A copy of the press release announcing Dr. Landry’s resignation
is furnished as Exhibit 99.01.
The Company’s meeting with the U.S. Food and Drug Administration
(“FDA”) to discuss the rationale and additional data to support continued Breakthrough Therapy designation for the
Company’s lead product candidate originally scheduled for June 2019 has been rescheduled to August 2019.
Item 9.01
|
Financial Statements and Exhibits.
|
(d)
|
|
Exhibit
No.
|
|
Description.
|
|
|
|
|
|
99.01
|
|
Press Release dated May 17, 2019, issued by the Company
|
SIGNATURE
Pursuant to the requirement
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
TONIX
PHARMACEUTICALS HOLDING CORP.
|
|
|
Date: May 17, 2019
|
By:
/s/ Bradley Saenger
|
|
Bradley Saenger
|
|
Chief Financial Officer
|
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Feb 2024 to Mar 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Mar 2023 to Mar 2024